Evidence map›Paper›PMID 38633244›Full record

ArticleFrontiers in immunology2024

Dry and liquid formulations of IBT-V02, a novel multi-component toxoid vaccine, are effective against

Yu Wang, Ipsita Mukherjee, Arundhathi Venkatasubramaniam, Dustin Dikeman, Nicholas Orlando, Jing Zhang, Roger Ortines, Mark Mednikov, Shardulendra P Sherchand, Tulasikumari Kanipakala and 7 more

Registry-linked trialOpen access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in immunology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06719219 (A Phase I, Randomized, Double-Blinded and Controlled Trial to Evaluate Safety and Immunogenicity of an Investigational Multicomponent Staphylococcus Aureus Toxoid Vaccine), which is not on this map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.4field-weighted citation impact, top 42% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT06719219 phase1completednot on this mapstarted 2025, after this paper: background citation

A Phase I, Randomized, Double-Blinded and Controlled Trial to Evaluate Safety and Immunogenicity of an Investigational Multicomponent Staphylococcus Aureus Toxoid Vaccine (LTB-SA7) in Healthy Adults.

TypeinterventionalSponsorLimmaTech Biologics AGRan2025 to 2026Enrolled129ConditionsStaphylococcus (S.) Aureus InfectionArmsLTB-SA7, Placebo
3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 citations in OpenAlex.

  1. Microorganisms · 2025
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors at 3 institutions in 1 country.

Yu Wang *Department of Dermatology, Johns Hopkins University, Baltimore, MD, United States.
Ipsita Mukherjee *Integrated Biotherapeutics Inc., Rockville, MD, United States.
Arundhathi VenkatasubramaniamIntegrated Biotherapeutics Inc., Rockville, MD, United States.
Dustin DikemanDepartment of Dermatology, Johns Hopkins University, Baltimore, MD, United States.
Nicholas OrlandoDepartment of Dermatology, Johns Hopkins University, Baltimore, MD, United States.
Jing ZhangDepartment of Dermatology, Johns Hopkins University, Baltimore, MD, United States.
Roger OrtinesIntegrated Biotherapeutics Inc., Rockville, MD, United States.
Mark MednikovIntegrated Biotherapeutics Inc., Rockville, MD, United States.
Shardulendra P SherchandIntegrated Biotherapeutics Inc., Rockville, MD, United States.
Tulasikumari KanipakalaIntegrated Biotherapeutics Inc., Rockville, MD, United States.
Thao LeCenter for Precision Medicine Research, Marshfield Clinic Research Institute, Marshfield, WI, United States.
Sanjay ShuklaCenter for Precision Medicine Research, Marshfield Clinic Research Institute, Marshfield, WI, United States.
Mark KetnerEngineered Biopharmaceuticals, Danville, VA, United States.
Rajan P AdhikariIntegrated Biotherapeutics Inc., Rockville, MD, United States.
Hatice KarauzumIntegrated Biotherapeutics Inc., Rockville, MD, United States.
M Javad AmanIntegrated Biotherapeutics Inc., Rockville, MD, United States.
Nathan K ArcherDepartment of Dermatology, Johns Hopkins University, Baltimore, MD, United States.
Integrated BioTherapeutics (United States) · USJohns Hopkins University · USMarshfield Clinic · US

Funding

Multivalent Toxoid Vaccine for recurrent Staphylococccus aureus diseaseR01AI111205 · NIAID · INTEGRATED BIOTHERAPEUTICS, INC. · PI M Javad Aman · 2015 to 2026
$6.9M
Protective versus deleterious immune responses that impact vaccine efficacy against Staphylococcus aureus bloodstream infectionR01AI146177 · NIAID · INTEGRATED BIOTHERAPEUTICS, INC. · PI AMAN, M JAVAD, ARCHER, NATHAN K. · 2020 to 2024
$3.5M
IL-36 responses in Staphylococcus aureus driven skin inflammationR01AR073665 · NIAMS · JOHNS HOPKINS UNIVERSITY · PI ARCHER, NATHAN K. · 2018 to 2022
$1.8M
NIAID NIH HHS R01 AI111205NIAID NIH HHS R01 AI146177NIAMS NIH HHS R01 AR073665
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Methicillin-Resistant Staphylococcus aureusStaphylococcal InfectionsAnimalsAnti-Bacterial AgentsBacterial VaccinesDeveloping CountriesMiceRabbitsStaphylococcus aureusToxoidsAnti-Bacterial AgentsBacterial VaccinesToxoidsIBT-V02LMICneutralizing antibodiespreclinical infection modelsStaphylococcus aureustoxinsvaccine development

Identifiers

PMID38633244
PMCPMC11022162
OpenAlexW4393856719

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.